Autocrine Complement Inhibits IL10-Dependent T-cell–Mediated Antitumor Immunity to Promote Tumor Progression
Open Access
- 31 August 2016
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 6 (9), 1022-1035
- https://doi.org/10.1158/2159-8290.cd-15-1412
Abstract
In contrast to its inhibitory effects on many cells, IL10 activates CD8+ tumor-infiltrating lymphocytes (TIL) and enhances their antitumor activity. However, CD8+ TILs do not routinely express IL10, as autocrine complement C3 inhibits IL10 production through complement receptors C3aR and C5aR. CD8+ TILs from C3-deficient mice, however, express IL10 and exhibit enhanced effector function. C3-deficient mice are resistant to tumor development in a T-cell– and IL10-dependent manner; human TILs expanded with IL2 plus IL10 increase the killing of primary tumors in vitro compared with IL2-treated TILs. Complement-mediated inhibition of antitumor immunity is independent of the programmed death 1/programmed death ligand 1 (PD-1/PD-L1) immune checkpoint pathway. Our findings suggest that complement receptors C3aR and C5aR expressed on CD8+ TILs represent a novel class of immune checkpoints that could be targeted for tumor immunotherapy. Moreover, incorporation of IL10 in the expansion of TILs and in gene-engineered T cells for adoptive cell therapy enhances their antitumor efficacy. Significance: Our data suggest novel strategies to enhance immunotherapies: a combined blockade of complement signaling by antagonists to C3aR, C5aR, and anti–PD-1 to enhance anti–PD-1 efficacy; a targeted IL10 delivery to CD8+ TILs using anti–PD-1–IL10 or anti-CTLA4–IL10 fusion proteins; and the addition of IL10 in TIL expansion for adoptive cellular therapy. Cancer Discov; 6(9); 1022–35. ©2016 AACR. See related commentary by Peng et al., p. 953. This article is highlighted in the In This Issue feature, p. 932Keywords
Other Versions
Funding Information
- NIH (AI074944)
This publication has 45 references indexed in Scilit:
- Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammationJCI Insight, 2013
- Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cellsThe Journal of Experimental Medicine, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- C5aR Expression in a Novel GFP Reporter Gene Knockin Mouse: Implications for the Mechanism of Action of C5aR Signaling in T Cell ImmunityThe Journal of Immunology, 2012
- Interleukin-10 Ablation Promotes Tumor Development, Growth, and MetastasisCancer Research, 2012
- Highly Activated Cytotoxic CD8 T Cells Express Protective IL-10 at the Peak of Coronavirus-Induced EncephalitisThe Journal of Immunology, 2011
- Modulation of the antitumor immune response by complementNature Immunology, 2008
- Locally produced C5a binds to T cell–expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosisBlood, 2008
- Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4(+) T cellsImmunity, 2008
- Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.JCI Insight, 1996